P2Y12 Inhibitor Monotherapy Combined With Colchicine Following PCI in ACS Patients: The MACT Pilot Study

Lee, Seung-Yul, Jeong, Young-Hoon, Ho Yun, Kyeong, Young Cho, Jae, Gorog, Diana, Angiolillo, Dominick J., Jin Won, Kim and Jang, Yangsoo (2023) P2Y12 Inhibitor Monotherapy Combined With Colchicine Following PCI in ACS Patients: The MACT Pilot Study. JACC: Cardiovascular Interventions, 16 (15). pp. 1845-1855. ISSN 1876-7605
Copy

This proof-of-concept pilot trial investigated the feasibility of ticagrelor or prasugrel P2Y12 inhibitor monotherapy combined with colchicine immediately after PCI in ACS patients. The day after PCI, aspirin was replaced with low-dose colchicine (0.6 mg daily) on ticagrelor or prasugrel maintenance. Among 200 ACS patients enrolled, stent thrombosis occurred in two patients for 3 months. High platelet reactivity assessed by VerifyNow assay was low at discharge and hs-CRP levels decreased significantly within 1 month after PCI. Accordingly, P2Y12 inhibitor mono antiplatelet and colchicine therapy is feasible in ACS patients undergoing PCI and associated with favorable platelet function and inflammatory profiles.


picture_as_pdf
Manuscript_R2_Clean.pdf
subject
Submitted Version
copyright
Available under Unspecified

View Download

Atom BibTeX OpenURL ContextObject in Span OpenURL ContextObject Dublin Core MPEG-21 DIDL Data Cite XML EndNote HTML Citation METS MODS RIOXX2 XML Reference Manager Refer ASCII Citation
Export

Downloads